BioStrand Omics Analysis Blog

Our omics analysis blog brings insights into genetics and genomics research solutions, and their leading role in the development of this industry.

Explained: A brief look into AlphaFold 2

Sébastien Lemal PhD | August 3, 2022

The year 2021 has been a wild ride for structural biologists, with the advent of AlphaFold2,...

AI-powered genomics to advance precision medicine

Dr Ingrid Brands, CEO | July 27, 2022

Sir William Osler, often called the father of modern medicine, was among the first to articulate a ...

AI, NLP and the ROI of drug development

Dr Ingrid Brands, CEO | July 20, 2022

The out-of-pocket R&D costs of developing a single drug, whether successfully launched or not, are...

Accelerating pharma R&D and innovation through technology partnerships

Dr Ingrid Brands, CEO | July 13, 2022

Biopharmas are increasingly turning to alliances & partnerships to drive external innovation....

Functional multiomics and antibody discovery

Dr Ingrid Brands, CEO | July 6, 2022

Genomics is the forerunner of all omics technologies, first introduced in 1987 as the name of a new...

Subscribe to our blog

The BioStrand Interviews: Meet Illia Panin

BioStrand | June 29, 2022

Illia got started with frontend development when it was just static HTML, CSS, basic JavaScript and...

Computational Antibody Design: The Future Of Antibody Discovery

Dr Ingrid Brands, CEO | June 22, 2022

In 2021, the FDA approved the 100th monoclonal antibody product, marking a significant milestone...

Improving Drug Safety with Adverse Event Detection Using NLP

Dr Ingrid Brands, CEO | June 15, 2022

It is estimated that Adverse Events (AEs) are likely one of the 10 leading causes of death and...

A Hybrid Approach to NLP in Drug Discovery

Dr Ingrid Brands, CEO | June 8, 2022

Artificial Intelligence-powered technologies like NLP are becoming critical to the pharmaceutical...

AI in early phase drug development

Dr Ingrid Brands, CEO | June 1, 2022

AI technologies are currently the most disruptive trend in the pharmaceutical industry. Over the...

The BioStrand Interviews: Meet Yegor Korovin

BioStrand | May 25, 2022

Yegor graduated with a Bachelor of Science degree in Physics before transitioning to a Masters in...